Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
Neurosurgery ; 93(5): 1180-1191, 2023 Nov 01.
Article in English | MEDLINE | ID: mdl-37265342

ABSTRACT

BACKGROUND AND OBJECTIVES: Targeted muscle reinnervation (TMR) and regenerative peripheral nerve interface (RPNI) surgeries manage neuroma pain; however, there remains considerable discord regarding the best treatment strategy. We provide a direct comparison of TMR and RPNI surgery using a rodent model for the treatment of neuroma pain. METHODS: The tibial nerve of 36 Fischer rats was transected and secured to the dermis to promote neuroma formation. Pain was assessed using mechanical stimulation at the neuroma site (direct pain) and von Frey analysis at the footpad (to assess tactile allodynia from collateral innervation). Once painful neuromas were detected 6 weeks later, animals were randomized to experimental groups: (a) TMR to the motor branch to biceps femoris, (b) RPNI with an extensor digitorum longus graft, (c) neuroma excision, and (d) neuroma in situ. The TMR/RPNIs were harvested to confirm muscle reinnervation, and the sensory ganglia and nerves were harvested to assess markers of regeneration, pain, and inflammation. RESULTS: Ten weeks post-TMR/RPNI surgery, animals had decreased pain scores compared with controls ( P < .001) and they both demonstrated neuromuscular junction reinnervation. Compared with neuroma controls, immunohistochemistry showed that sensory neuronal cell bodies of TMR and RPNI showed a decrease in regeneration markers phosphorylated cyclic AMP receptor binding protein and activation transcription factor 3 and pain markers transient receptor potential vanilloid 1 and neuropeptide Y ( P < .05). The nerve and dorsal root ganglion maintained elevated Iba-1 expression in all cohorts. CONCLUSION: RPNI and TMR improved pain scores after neuroma resection suggesting both may be clinically feasible techniques for improving outcomes for patients with nerve injuries or those undergoing amputation.


Subject(s)
Amputation, Surgical , Neuroma , Animals , Humans , Rats , Muscle, Skeletal/innervation , Neuroma/prevention & control , Neuroma/surgery , Pain , Tibial Nerve
2.
Sci Rep ; 12(1): 20995, 2022 12 05.
Article in English | MEDLINE | ID: mdl-36470947

ABSTRACT

Multiple Sclerosis (MS) is an autoimmune disease with notable sex differences. Women are not only more likely to develop MS but are also more likely than men to experience neuropathic pain in the disease. It has been postulated that neuropathic pain in MS can originate in the peripheral nervous system at the level of the dorsal root ganglia (DRG), which houses primary pain sensing neurons (nociceptors). These nociceptors become hyperexcitable in response to inflammation, leading to peripheral sensitization and eventually central sensitization, which maintains pain long-term. The mouse model experimental autoimmune encephalomyelitis (EAE) is a good model for human MS as it replicates classic MS symptoms including pain. Using EAE mice as well as naïve primary mouse DRG neurons cultured in vitro, we sought to characterize sex differences, specifically in peripheral sensory neurons. We found sex differences in the inflammatory profile of the EAE DRG, and in the TNFα downstream signaling pathways activated intracellularly in cultured nociceptors. We also found increased cell death with TNFα treatment. Given that TNFα signaling has been shown to initiate intrinsic apoptosis through mitochondrial disruption, this led us to investigate sex differences in the mitochondria's response to TNFα. Our results demonstrate that male sensory neurons are more sensitive to mitochondrial stress, making them prone to neuronal injury. In contrast, female sensory neurons appear to be more resistant to mitochondrial stress and exhibit an inflammatory and regenerative phenotype that may underlie greater nociceptor hyperexcitability and pain. Understanding these sex differences at the level of the primary sensory neuron is an important first step in our eventual goal of developing sex-specific treatments to halt pain development in the periphery before central sensitization is established.


Subject(s)
Encephalomyelitis, Autoimmune, Experimental , Ganglia, Spinal , Multiple Sclerosis , Neuralgia , Sex Characteristics , Animals , Female , Humans , Male , Mice , Encephalomyelitis, Autoimmune, Experimental/physiopathology , Ganglia, Spinal/physiopathology , Multiple Sclerosis/physiopathology , Neuralgia/etiology , Neuralgia/physiopathology , Nociceptors/metabolism , Tumor Necrosis Factor-alpha/metabolism
3.
Eur J Neurosci ; 56(8): 5177-5190, 2022 10.
Article in English | MEDLINE | ID: mdl-36083288

ABSTRACT

Multiple sclerosis (MS) and its animal models are characterized by cellular inflammation within the central nervous system (CNS). The sources and consequences of this inflammation are currently not completely understood. Critical signs and mediators of CNS inflammation are reactive oxygen species (ROS) that promote inflammation. ROS originate from a variety of redox-reactive enzymes, one class of which catalyses oxidative protein folding within the endoplasmic reticulum (ER). Here, the unfolded protein response and other signalling mechanisms maintain a balance between ROS producers such as ER oxidoreductin 1α (Ero1α) and antioxidants such as glutathione peroxidase 8 (GPx8). The role of ROS production within the ER has so far not been examined in the context of MS. In this manuscript, we examined how components of the ER redox network change upon MS and experimental autoimmune encephalomyelitis (EAE). We found that unlike GPx8, Ero1α increases within both MS and EAE astrocytes, in parallel with an imbalance of other oxidases such of GPx7, and that no change was observed within neurons. This imbalance of ER redox enzymes can reduce the lifespan of astrocytes, while neurons are not affected. Therefore, Ero1α induction makes astrocytes vulnerable to oxidative stress in the MS and EAE pathologies.


Subject(s)
Encephalomyelitis, Autoimmune, Experimental , Multiple Sclerosis , Animals , Astrocytes/metabolism , Disease Models, Animal , Glutathione Peroxidase/metabolism , Inflammation , Reactive Oxygen Species/metabolism
4.
FASEB J ; 34(9): 12577-12598, 2020 09.
Article in English | MEDLINE | ID: mdl-32677089

ABSTRACT

Neuropathic pain is a common symptom of multiple sclerosis (MS) and current treatment options are ineffective. In this study, we investigated whether endoplasmic reticulum (ER) stress in dorsal root ganglia (DRG) contributes to pain hypersensitivity in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS. Inflammatory cells and increased levels of ER stress markers are evident in post-mortem DRGs from MS patients. Similarly, we observed ER stress in the DRG of mice with EAE and relieving ER stress with a chemical chaperone, 4-phenylbutyric acid (4-PBA), reduced pain hypersensitivity. In vitro, 4-PBA and the selective PERK inhibitor, AMG44, normalize cytosolic Ca2+ transients in putative DRG nociceptors. We went on to assess disease-mediated changes in the functional properties of Ca2+ -sensitive BK-type K+ channels in DRG neurons. We found that the conductance-voltage (GV) relationship of BK channels was shifted to a more positive voltage, together with a more depolarized resting membrane potential in EAE cells. Our results suggest that ER stress in sensory neurons of MS patients and mice with EAE is a source of pain and that ER stress modulators can effectively counteract this phenotype.


Subject(s)
Encephalomyelitis, Autoimmune, Experimental/metabolism , Endoplasmic Reticulum Stress , Ganglia, Spinal/metabolism , Large-Conductance Calcium-Activated Potassium Channels/metabolism , Neuralgia/metabolism , Nociceptors/metabolism , Adult , Aged , Aged, 80 and over , Animals , Female , Ganglia, Spinal/pathology , Humans , Mice , Mice, Inbred C57BL , Middle Aged , Multiple Sclerosis/metabolism , Multiple Sclerosis/pathology , Netherlands , Nociceptors/pathology
5.
eNeuro ; 6(2)2019.
Article in English | MEDLINE | ID: mdl-30957012

ABSTRACT

Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central nervous system. Patients with MS typically present with visual, motor, and sensory deficits. However, an additional complication of MS in large subset of patients is neuropathic pain. To study the underlying immune-mediated pathophysiology of pain in MS we employed the myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalitis (EAE) model in mice. Since sensory neurons are crucial for nociceptive transduction, we investigated the effect of this disease on sensory neurons of the lumbar dorsal root ganglia (DRG). Here, we report the disease was associated with activation of the complement system and the NLRP3 inflammasome in the DRG. We further observe a transient increase in the number of complement component 5a receptor 1-positive (C5aR1+) immune cells, CD4+ T-cells, and Iba1+ macrophages in the DRG. The absence of any significant change in the levels of mRNA for myelin proteins in the DRG and the sciatic nerve suggests that demyelination in the PNS is not a trigger for the immune response in the DRG. However, we did observe an induction of activating transcription factor 3 (ATF3) at disease onset and chronic disruption of cytoskeletal proteins in the DRG demonstrating neuronal injury in the PNS in response to the disease. Electrophysiological analysis revealed the emergence of hyperexcitability in medium-to-large (≥26 µm) diameter neurons, especially at the onset of MOG-EAE signs. These results provide conclusive evidence of immune activation, neuronal injury, and peripheral sensitization in MOG-EAE, a model classically considered to be centrally mediated.


Subject(s)
Encephalomyelitis, Autoimmune, Experimental/physiopathology , Ganglia, Spinal/physiopathology , Multiple Sclerosis/physiopathology , Sensory Receptor Cells/pathology , Animals , Encephalomyelitis, Autoimmune, Experimental/immunology , Encephalomyelitis, Autoimmune, Experimental/pathology , Ganglia, Spinal/pathology , Mice , Multiple Sclerosis/immunology , Multiple Sclerosis/pathology , Myelin-Oligodendrocyte Glycoprotein/immunology , Neuralgia/physiopathology , T-Lymphocytes
6.
Pain ; 160(4): 870-881, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30540622

ABSTRACT

Multiple sclerosis (MS) is an inflammatory, neurodegenerative autoimmune disease associated with sensory and motor dysfunction. Although estimates vary, ∼50% of patients with MS experience pain during their disease. The mechanisms underlying the development of pain are not fully understood, and no effective treatment for MS-related pain is available. Previous work from our laboratory demonstrated that voluntary exercise (wheel running) can reduce nociceptive behaviours at the disease onset in female mice with experimental autoimmune encephalomyelitis (EAE), an animal model used to study the immunopathogenesis of MS. However, given the established sex differences in the underlying mechanisms of chronic pain and MS, we wanted to investigate whether wheel running would also be effective at preventing nociceptive behaviours in male mice with EAE. C57BL/6 mice of both sexes were given access to running wheels for 1 hour/day until the disease onset, when nociceptive behaviour was assessed using von Frey hairs. Daily running effectively reduced nociceptive behaviour in female mice, but not in male mice. We explored the potential biological mechanisms for these effects and found that the reduction in nociceptive behaviour in female mice was associated with reduced levels of inflammatory cytokines from myelin-reactive T cells as well as reduced dorsal root ganglia excitability as seen by decreased calcium responses. These changes were not seen in male mice. Instead, running increased the levels of inflammatory cytokines and potentiated Ca responses in dorsal root ganglia cells. Our results show that voluntary wheel running has sex-dependent effects on nociceptive behaviour and inflammatory responses in male and female mice with EAE.


Subject(s)
Encephalomyelitis, Autoimmune, Experimental/rehabilitation , Nociception/physiology , Physical Conditioning, Animal/methods , Sex Characteristics , Animals , Antibodies/pharmacology , Cell Proliferation/physiology , Cells, Cultured , Culture Media, Conditioned/pharmacology , Cytokines/immunology , Cytokines/metabolism , Disease Models, Animal , Encephalomyelitis, Autoimmune, Experimental/pathology , Female , Ganglia, Spinal/cytology , Hyperalgesia/physiopathology , Male , Mice , Mice, Inbred C57BL , Pain Threshold/physiology , Sensory Receptor Cells/metabolism , Spleen/cytology
7.
Neuroscience ; 383: 205-215, 2018 07 15.
Article in English | MEDLINE | ID: mdl-29752984

ABSTRACT

The putative strong anti-nociceptive properties of the antidepressant phenelzine (PLZ) have not been widely explored as a treatment for pain. Antinociceptive effects of PLZ were identified in the formalin model of tonic pain (Mifflin et al., 2016) and in allodynia associated with experimental autoimmune encephalomyelitis, (EAE) a mouse model of multiple sclerosis (Potter et al., 2016). Here, we further clarify the specific types of stimuli and contexts in which PLZ modulates nociceptive sensitivity. Our findings indicate that PLZ selectively inhibits ongoing inflammatory pain while sparing transient reflexive and acute nociception. We also investigated the cellular mechanisms of action of PLZ in the dorsal horn, and as expected of a monoamine-oxidase inhibitor, PLZ increased serotonin (5HT) immunoreactivity. We next used two approaches to test the hypothesis that PLZ inhibits the activation of spinal nociresponsive neurons. First, we evaluated the formalin-evoked protein expression of the immediate early gene, c-fos. PLZ reduced Fos expression in the superficial dorsal horn. Second, we evaluated the effects of PLZ on intracellular calcium responses to superfusion of glutamate (0.3-1.0 mM) in an ex vivo lumbar spinal cord slice preparation. Superfusion with PLZ (100-300 µM) reduced 1 mM glutamate-evoked calcium responses. This was blocked by pretreatment with the 5HT1A-receptor antagonist WAY-100,635, but not the alpha-2 adrenergic antagonist idazoxan. We conclude that PLZ exerts antinociceptive effects through a 5-HT/5HT1AR-dependent inhibition of neuronal responses within nociceptive circuits of the dorsal horn.


Subject(s)
Antidepressive Agents/pharmacology , Neurons/drug effects , Phenelzine/pharmacology , Spinal Cord Dorsal Horn/drug effects , Animals , Female , Hyperalgesia/metabolism , Mice , Mice, Inbred C57BL , Neurons/metabolism , Pain/metabolism , Receptors, Serotonin, 5-HT1/metabolism , Serotonin/metabolism , Spinal Cord Dorsal Horn/metabolism
8.
Rev Saude Publica ; 51: 71, 2017 Jul 20.
Article in English, Portuguese | MEDLINE | ID: mdl-28746572

ABSTRACT

OBJECTIVE: To quantify the intensity adopted by walkers in public squares and check the occurrence and magnitude of post-exercise hypotension in the spontaneously adopted intensity and in a prescribed intensity. METHODS: In 98 volunteers (38 of them being hypertensive), walkers in public squares of the city of João Pessoa, State of Paraíba, Brazil, we have identified the intensity of a usual training monitored by heart rate and we have investigated the occurrence and magnitude of post-exercise hypotension. Subsequently, participants were instructed to walk with moderate intensity. Blood pressure was measured after rest and during post-exercise recovery. RESULTS: Of the total participants, 41% of the hypertensive and 36% of the normotensive individuals walked with light intensity. With the prescription, intensity increased to 55% and 52%, for the hypertensive and normotensive individuals, respectively. In the usual and prescribed intensity, the hypertensive individuals had post-exercise hypotension of -3.7±11.6 mmHg and -4.72±12.8 mmHg, respectively. There was no correlation between post-exercise hypotension and the initial systolic component of the hypertensive individuals (r2 = 0.2; p < 0.002). CONCLUSIONS: Walkers in public squares choose light intensity for walking. When they exercise with the prescribed intensity, they increase the intensity, but the magnitude of the PEH is not increase with this guidance. OBJETIVO: Quantificar a intensidade adotada por caminhantes em praças públicas e verificar a ocorrência e a magnitude da hipotensão pós-exercício na intensidade espontaneamente adotada e em uma intensidade prescrita. MÉTODOS: Em 98 voluntários (38 hipertensos), caminhantes em praças públicas da cidade de João Pessoa, PB, identificamos a intensidade de um treino habitual monitorada por meio da frequência cardíaca e averiguamos a ocorrência e magnitude de hipotensão pós-exercício. Posteriormente, os participantes foram instruídos a caminhar com intensidade moderada. A pressão arterial foi aferida após o repouso e durante a recuperação pós-exercício. RESULTADOS: Do total de participantes, 41% dos hipertensos e 36% dos normotensos caminhavam com intensidade leve. Com a prescrição, a intensidade aumentou para 55% e 52%, para hipertensos e normotensos. Na intensidade habitual e prescrita, os hipertensos obtiveram hipotensão pós-exercício de -3,7±11,6 mmHg e -4,72±12,8 mmHg. Houve correlação entre hipotensão pós-exercício e o componente sistólico inicial dos hipertensos (r2 = 0,2; p < 0,002). CONCLUSÕES: Caminhantes em praças públicas selecionam intensidade leve para realização de caminhada. Quando realizam exercício com intensidade prescrita, aumentam discretamente a intensidade, mas não obtêm aumento da magnitude da HPE com esta orientação.


Subject(s)
Hypertension/physiopathology , Post-Exercise Hypotension/physiopathology , Walking/physiology , Adult , Analysis of Variance , Blood Pressure/physiology , Case-Control Studies , Cross-Sectional Studies , Exercise Therapy , Female , Heart Rate/physiology , Humans , Male , Middle Aged , Statistics, Nonparametric , Time Factors
9.
Neuroscience ; 344: 178-186, 2017 03 06.
Article in English | MEDLINE | ID: mdl-28057537

ABSTRACT

Patients with multiple sclerosis (MS) often complain of neuropathic pain. According to the Gate Control Theory of Pain, spinal networks of GABAergic inhibitory interneurons are important in modulating nociceptive inputs from the periphery. Na+-K+-2Cl- co-transporter 1 (NKCC1) and K+-Cl- co-transporter 2 (KCC2) generally dictate the tone of GABA/glycine inhibition by regulating intracellular chloride concentrations. In this study, we investigated the role of NKCC1 and KCC2 in neuropathic pain observed in the animal model, experimental autoimmune encephalomyelitis (EAE), a commonly used model to study the pathophysiology of MS. Quantitative real-time polymerase chain reactions (qRT-PCR) analysis revealed no change in NKCC1 mRNA transcripts in dorsal root ganglia throughout EAE disease course. However, NKCC1 and KCC2 mRNA levels in the dorsal spinal cord were significantly reduced at disease onset and peak only to recover by the chronic time point. Similarly, Western blot data revealed a significant downregulation of NKCC1 and KCC2 in the dorsal spinal cord at disease onset but an upregulation of NKCC1 protein in the dorsal root ganglia at this time point. Treatment with bumetanide, an NKCC inhibitor, had no effect on mechanical hypersensitivity seen in mice with EAE even though it reversed the changes in the levels of NKCC1 and KCC2. We noted that bumetanide treatment, while effective at reversing the changes in monomeric KCC2 levels was ineffective at reversing the changes in oligomeric KCC2 which remained repressed. These results indicate that mechanical hypersensitivity in EAE is not mediated by altered levels of NKCC1.


Subject(s)
Encephalomyelitis, Autoimmune, Experimental/metabolism , Hyperalgesia/metabolism , Neuralgia/metabolism , Solute Carrier Family 12, Member 2/metabolism , Spinal Cord/metabolism , Symporters/metabolism , Animals , Bumetanide/pharmacology , Disease Progression , Encephalomyelitis, Autoimmune, Experimental/drug therapy , Encephalomyelitis, Autoimmune, Experimental/pathology , Female , Ganglia, Spinal/drug effects , Ganglia, Spinal/metabolism , Ganglia, Spinal/pathology , Gene Expression/drug effects , Hyperalgesia/drug therapy , Hyperalgesia/pathology , Mice, Inbred C57BL , Myelin-Oligodendrocyte Glycoprotein , Neuralgia/drug therapy , Neuralgia/pathology , Peptide Fragments , RNA, Messenger/metabolism , Sodium Potassium Chloride Symporter Inhibitors/pharmacology , Spinal Cord/drug effects , Spinal Cord/pathology , K Cl- Cotransporters
10.
Rev. saúde pública (Online) ; 51: 71, 2017. tab, graf
Article in English | LILACS | ID: biblio-903227

ABSTRACT

ABSTRACT OBJECTIVE To quantify the intensity adopted by walkers in public squares and check the occurrence and magnitude of post-exercise hypotension in the spontaneously adopted intensity and in a prescribed intensity. METHODS In 98 volunteers (38 of them being hypertensive), walkers in public squares of the city of João Pessoa, State of Paraíba, Brazil, we have identified the intensity of a usual training monitored by heart rate and we have investigated the occurrence and magnitude of post-exercise hypotension. Subsequently, participants were instructed to walk with moderate intensity. Blood pressure was measured after rest and during post-exercise recovery. RESULTS Of the total participants, 41% of the hypertensive and 36% of the normotensive individuals walked with light intensity. With the prescription, intensity increased to 55% and 52%, for the hypertensive and normotensive individuals, respectively. In the usual and prescribed intensity, the hypertensive individuals had post-exercise hypotension of -3.7±11.6 mmHg and -4.72±12.8 mmHg, respectively. There was no correlation between post-exercise hypotension and the initial systolic component of the hypertensive individuals (r2 = 0.2; p < 0.002). CONCLUSIONS Walkers in public squares choose light intensity for walking. When they exercise with the prescribed intensity, they increase the intensity, but the magnitude of the PEH is not increase with this guidance.


RESUMO OBJETIVO Quantificar a intensidade adotada por caminhantes em praças públicas e verificar a ocorrência e a magnitude da hipotensão pós-exercício na intensidade espontaneamente adotada e em uma intensidade prescrita. MÉTODOS Em 98 voluntários (38 hipertensos), caminhantes em praças públicas da cidade de João Pessoa, PB, identificamos a intensidade de um treino habitual monitorada por meio da frequência cardíaca e averiguamos a ocorrência e magnitude de hipotensão pós-exercício. Posteriormente, os participantes foram instruídos a caminhar com intensidade moderada. A pressão arterial foi aferida após o repouso e durante a recuperação pós-exercício. RESULTADOS Do total de participantes, 41% dos hipertensos e 36% dos normotensos caminhavam com intensidade leve. Com a prescrição, a intensidade aumentou para 55% e 52%, para hipertensos e normotensos. Na intensidade habitual e prescrita, os hipertensos obtiveram hipotensão pós-exercício de -3,7±11,6 mmHg e -4,72±12,8 mmHg. Houve correlação entre hipotensão pós-exercício e o componente sistólico inicial dos hipertensos (r2 = 0,2; p < 0,002). CONCLUSÕES Caminhantes em praças públicas selecionam intensidade leve para realização de caminhada. Quando realizam exercício com intensidade prescrita, aumentam discretamente a intensidade, mas não obtêm aumento da magnitude da HPE com esta orientação.


Subject(s)
Humans , Male , Female , Adult , Walking/physiology , Post-Exercise Hypotension/physiopathology , Hypertension/physiopathology , Time Factors , Blood Pressure/physiology , Case-Control Studies , Cross-Sectional Studies , Analysis of Variance , Statistics, Nonparametric , Exercise Therapy , Heart Rate/physiology , Middle Aged
11.
J Neuroinflammation ; 13(1): 142, 2016 06 10.
Article in English | MEDLINE | ID: mdl-27282914

ABSTRACT

BACKGROUND: Chronic neuropathic pain is a common symptom of multiple sclerosis (MS). MOG35-55-induced experimental autoimmune encephalomyelitis (EAE) has been used as an animal model to investigate the mechanisms of pain in MS. Previous studies have implicated sensitization of spinal nociceptive networks in the pathogenesis of pain in EAE. However, the involvement of supraspinal sites of nociceptive integration, such as the primary somatosensory cortex (S1), has not been defined. We therefore examined functional, structural, and immunological alterations in S1 during the early stages of EAE, when pain behaviors first appear. We also assessed the effects of the antidepressant phenelzine (PLZ) on S1 alterations and nociceptive (mechanical) sensitivity in early EAE. PLZ has been shown to restore central nervous system (CNS) tissue concentrations of GABA and the monoamines (5-HT, NA) in EAE. We hypothesized that PLZ treatment would also normalize nociceptive sensitivity in EAE by restoring the balance of excitation and inhibition (E-I) in the CNS. METHODS: We used in vivo flavoprotein autofluorescence imaging (FAI) to assess neural ensemble responses in S1 to vibrotactile stimulation of the limbs in early EAE. We also used immunohistochemistry (IHC), and Golgi-Cox staining, to examine synaptic changes and neuroinflammation in S1. Mechanical sensitivity was assessed at the clinical onset of EAE with Von Frey hairs. RESULTS: Mice with early EAE exhibited significantly intensified and expanded FAI responses in S1 compared to controls. IHC revealed increased vesicular glutamate transporter (VGLUT1) expression and disrupted parvalbumin+ (PV+) interneuron connectivity in S1 of EAE mice. Furthermore, peri-neuronal nets (PNNs) were significantly reduced in S1. Morphological analysis of excitatory neurons in S1 revealed increased dendritic spine densities. Iba-1+ cortical microglia were significantly elevated early in the disease. Chronic PLZ treatment was found to normalize mechanical thresholds in EAE. PLZ also normalized S1 FAI responses, neuronal morphologies, and cortical microglia numbers and attenuated VGLUT1 reactivity-but did not significantly attenuate the loss of PNNs. CONCLUSIONS: These findings implicate a pro-excitatory shift in the E-I balance of the somatosensory CNS, arising early in the pathogenesis EAE and leading to large-scale functional and structural plasticity in S1. They also suggest a novel antinociceptive effect of PLZ treatment.


Subject(s)
Encephalomyelitis, Autoimmune, Experimental/complications , Neuralgia/etiology , Neuralgia/pathology , Pain Threshold/physiology , Somatosensory Cortex/pathology , Synapses/metabolism , Animals , Antidepressive Agents/pharmacology , Antidepressive Agents/therapeutic use , Calcium-Binding Proteins/metabolism , Disease Models, Animal , Encephalomyelitis, Autoimmune, Experimental/chemically induced , Encephalomyelitis, Autoimmune, Experimental/immunology , Female , Freund's Adjuvant/toxicity , Hyperalgesia/etiology , Mice , Mice, Inbred C57BL , Microfilament Proteins/metabolism , Myelin-Oligodendrocyte Glycoprotein/immunology , Myelin-Oligodendrocyte Glycoprotein/toxicity , Neuralgia/drug therapy , Neurons/cytology , Neurons/metabolism , Neurons/ultrastructure , Pain Measurement/drug effects , Pain Threshold/drug effects , Parvalbumins/metabolism , Peptide Fragments/immunology , Peptide Fragments/toxicity , Phenelzine/pharmacology , Phenelzine/therapeutic use , Plant Lectins/metabolism , Receptors, N-Acetylglucosamine/metabolism , Somatosensory Cortex/drug effects , Somatosensory Cortex/ultrastructure , Synapses/pathology , Synapses/ultrastructure
12.
Exp Neurol ; 271: 279-90, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26033473

ABSTRACT

Multiple sclerosis (MS) is classically defined by motor deficits, but it is also associated with the secondary symptoms of pain, depression, and anxiety. Up to this point modifying these secondary symptoms has been difficult. There is evidence that both MS and the animal model experimental autoimmune encephalomyelitis (EAE), commonly used to study the pathophysiology of the disease, can be modulated by exercise. To examine whether limited voluntary wheel running could modulate EAE disease progression and the co-morbid symptoms of pain, mice with EAE were allowed access to running wheels for 1h every day. Allowing only 1h every day of voluntary running led to a significant delay in the onset of clinical signs of the disease. The development of mechanical allodynia was assessed using Von Frey hairs and indicated that wheel running had a modest positive effect on the pain hypersensitivity associated with EAE. These behavioral changes were associated with reduced numbers of cFOS and phosphorylated NR1 positive cells in the dorsal horn of the spinal cord compared to no-run EAE controls. In addition, within the dorsal horn, voluntary wheel running reduced the number of infiltrating CD3(+) T-cells and reduced the overall levels of Iba1 immunoreactivity. Using high performance liquid chromatography (HPLC), we observed that wheel-running lead to significant changes in the spinal cord levels of the antioxidant glutathione. Oxidative stress has separately been shown to contribute to EAE disease progression and neuropathic pain. Together these results indicate that in mice with EAE, voluntary motor activity can delay the onset of clinical signs and reduce pain symptoms associated with the disease.


Subject(s)
Exercise Therapy/methods , Neuralgia/etiology , Neuralgia/rehabilitation , Neuritis, Autoimmune, Experimental/complications , Pain Threshold/physiology , Running/physiology , Animals , Antigens, CD/metabolism , Calcium-Binding Proteins/metabolism , Electron Transport Complex IV/metabolism , Female , Hyperalgesia/physiopathology , Hyperalgesia/rehabilitation , Mice , Mice, Inbred C57BL , Microfilament Proteins/metabolism , Motor Activity/physiology , Myelin-Oligodendrocyte Glycoprotein/toxicity , Nerve Tissue Proteins/metabolism , Neuritis, Autoimmune, Experimental/chemically induced , Neuritis, Autoimmune, Experimental/rehabilitation , Nitric Oxide Synthase Type II/metabolism , Peptide Fragments/toxicity , Proto-Oncogene Proteins c-fos/metabolism , Receptors, N-Methyl-D-Aspartate/metabolism , Statistics, Nonparametric
13.
Behav Brain Res ; 252: 302-11, 2013 Sep 01.
Article in English | MEDLINE | ID: mdl-23777648

ABSTRACT

Many symptoms in multiple sclerosis (MS) can be related to changes in the levels of key neurotransmitters. These neurotransmitters have a direct role in the maintenance of neurons and also have immunomodulatory properties. Previously we have shown that when treatment began prior to the onset of clinical signs, daily treatment with the monoamine oxidase (MAO) inhibitor phenelzine (PLZ), which also elevates CNS levels of GABA, lead to substantial behavioral improvements in the experimental autoimmune encephalomyelitis (EAE), the animal model for MS. To determine whether PLZ could have beneficial effects in an already established disease state, we conducted experiments in which PLZ treatment only began when mice with EAE exhibited the first clinical signs of the disease. Using this more clinically relevant treatment approach, we find that PLZ treatment can reduce the severity of clinical signs and improve exploratory behaviors for the duration of the experiment in mice with EAE. Treatment with PLZ did not affect the infiltration of CD4+ T-cells into the spinal cord nor did it reduce the degree of reactive gliosis as measured by Iba1 immunostaining. Beginning PLZ treatment after the start of clinical signs did however lead to significantly better 5-HT innervation density in the ventral horn of the spinal cord and also resulted in higher levels of GABA, dopamine and norepinephrine in the brain and spinal cord. These results indicate that even in an established EAE disease state, PLZ can have clinical benefits. These benefits likely derive from PLZ's ability to normalize the innervation to ventral horn motor neuron pools as well as the elevations in GABA and biogenic amines that have been shown to have anti-inflammatory properties.


Subject(s)
Encephalomyelitis, Autoimmune, Experimental/drug therapy , Monoamine Oxidase Inhibitors/therapeutic use , Phenelzine/therapeutic use , Treatment Outcome , Analysis of Variance , Animals , CD4 Antigens/metabolism , Central Nervous System/drug effects , Central Nervous System/metabolism , Central Nervous System/pathology , Chromatography, High Pressure Liquid , Disease Models, Animal , Dopamine/metabolism , Encephalomyelitis, Autoimmune, Experimental/chemically induced , Encephalomyelitis, Autoimmune, Experimental/immunology , Encephalomyelitis, Autoimmune, Experimental/pathology , Exploratory Behavior/drug effects , Female , Freund's Adjuvant/toxicity , Mice , Mice, Inbred C57BL , Monoamine Oxidase/metabolism , Myelin-Oligodendrocyte Glycoprotein/toxicity , Norepinephrine/metabolism , Peptide Fragments/toxicity , Rotarod Performance Test , Serotonin/metabolism , T-Lymphocytes/drug effects , T-Lymphocytes/metabolism , T-Lymphocytes/pathology , Time Factors , gamma-Aminobutyric Acid/metabolism
14.
J Neuroimmunol ; 256(1-2): 43-8, 2013 Mar 15.
Article in English | MEDLINE | ID: mdl-23385082

ABSTRACT

In the spinal cord, PKCγ is an important kinase found in a specific subset of excitatory interneurons in the superficial dorsal horn and in axons of the corticospinal tract (CST). The major interest in spinal PKCγ has been its influences on regulating pain sensitivity but its presence in the CST also indicates that it has a significant role in locomotor function. A hallmark feature of the animal model commonly used to study Multiple Sclerosis, experimental autoimmune encephalolomyelitis (EAE) are motor impairments associated with the disease. More recently, it has also become recognized that EAE is associated with significant changes in pain sensitivity. Given its role in generating pain hypersensitivity and its presence in a major tract controlling motor activity, we set out to characterize whether EAE was associated with changes PKCγ levels in the spinal cord. We show here that EAE triggers a significant reduction in the levels of PKCγ, primarily in the CST. We did not observe any significant changes in PKCγ levels in the superficial dorsal horn but in general the levels tended to be below control levels in this region. In a final experiment we assessed the levels of PKCγ in the spinal cord of EAE mice that had recovered gross locomotor function and compared this to the levels found in EAE mice with chronic deficits. Our findings demonstrate that PKCγ levels are dynamic and that in later stages of the disease, its expression is dependent on the degree of motor function in the model. Taken together these results suggest that PKCγ may be a useful marker in the disease to monitor the status of the CST.


Subject(s)
Encephalomyelitis, Autoimmune, Experimental/pathology , Gene Expression Regulation, Enzymologic/physiology , Protein Kinase C/metabolism , Pyramidal Tracts/enzymology , Animals , Biomarkers/metabolism , Disease Models, Animal , Encephalomyelitis, Autoimmune, Experimental/physiopathology , Female , Mice , Mice, Inbred C57BL , Time Factors
15.
Exp Neurol ; 241: 113-21, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23291347

ABSTRACT

Multiple sclerosis is associated with a high incidence of depression, cognitive impairments and neuropathic pain. Previously, we demonstrated that tactile allodynia is present at disease onset in an animal model of MS, experimental autoimmune encephalomyelitis (EAE). We have now monitored changes in object recognition in mice with EAE to determine if altered nociceptive sensitivity is also associated with behavioral signs indicative of cognitive impairment in this model. At the onset of clinical signs, mice with EAE showed impairments in the novel object recognition (NOR) assay, indicative of deficits in cognitive functioning early in the disease course. At the spinal level, we found increased gene expression for the cytokines IL-1ß, IL-6 and the glutamate transporter EAAT-2 that coincide with increased nociceptive sensitivity and deficits in object recognition. Increased levels of EAAT-2 mRNA appear to be a response to perturbed protein levels of the transporter as we found a loss of EAAT-2 protein levels in the spinal cord of EAE mice. To determine if changes in the levels of EAAT-2 were responsible for the observed changes in nociceptive sensitivity and cognitive deficits, we treated EAE mice with the ß-lactam antibiotic ceftriaxone, an agent known to increase glutamate transporter levels in vivo. Ceftriaxone prevented tactile hypersensitivity and normalized performance in the NOR assay in EAE mice. These findings highlight the important interrelationship between pain and cognitive function in the disease and suggest that targeting spinally mediated pain hypersensitivity is a novel therapeutic avenue to treat impairments in other higher order cortical processes.


Subject(s)
Encephalomyelitis, Autoimmune, Experimental/complications , Hyperalgesia/etiology , Pain Threshold/physiology , Recognition, Psychology/physiology , Analysis of Variance , Animals , Brain/drug effects , Brain/metabolism , Ceftriaxone/therapeutic use , Disease Models, Animal , Encephalomyelitis, Autoimmune, Experimental/chemically induced , Encephalomyelitis, Autoimmune, Experimental/drug therapy , Encephalomyelitis, Autoimmune, Experimental/pathology , Excitatory Amino Acid Transporter 2/genetics , Excitatory Amino Acid Transporter 2/metabolism , Exploratory Behavior/drug effects , Female , Freund's Adjuvant/toxicity , Gene Expression Regulation/drug effects , Hyperalgesia/drug therapy , Interleukin-1beta/genetics , Interleukin-1beta/metabolism , Interleukin-6/genetics , Interleukin-6/metabolism , Mice , Mice, Inbred C57BL , Motor Activity/drug effects , Motor Activity/physiology , Myelin-Oligodendrocyte Glycoprotein/toxicity , Pain Measurement , Pain Threshold/drug effects , Peptide Fragments/toxicity , RNA, Messenger/metabolism , Receptors, N-Methyl-D-Aspartate/metabolism , Recognition, Psychology/drug effects , Rotarod Performance Test , Spinal Cord/drug effects , Spinal Cord/metabolism , Time Factors
16.
Pain ; 154(1): 71-81, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23103436

ABSTRACT

Injury or disease affecting the spinal cord is often accompanied by abnormal, chronic pain. Recent estimates suggest that approximately 60% of patients with multiple sclerosis are affected by significant changes in pain sensitivity or experience ongoing neuropathic pain of unknown etiology. Chronic pain is also a significant concern after direct spinal cord trauma. Inflammatory events and the changes in astrocyte and microglia reactivity at the spinal level in response to injury or disease are now recognized as important processes that can initiate pain hypersensitivity. Changes in the structural integrity or permeability of the blood-brain barrier/blood-spinal cord barrier (BBB/BSCB) can facilitate the inflammatory events that result in these abnormal pain states. It remains unclear, however, whether chronic pain in these disorders is dependent on the influx of peripheral leukocytes or whether changes in the reactivity of resident glial cells within the central nervous system alone are sufficient. To address this question, we generated a model of perispinal inflammation that resulted in significant changes in the reactivity of resident astrocytes and microglia within the spinal cord but maintained the integrity of the BSCB. A number of similar changes at the behavioural and cellular level occur in this model that mimic the responses seen in animal models of multiple sclerosis or spinal cord injury (SCI). However, these changes are short lived and resolve over the course of a 2-week observation period. Our findings suggest that the chronicity of pain after injury or disease in the nervous system is dependent on the integrity of the BBB/BSCB.


Subject(s)
Astrocytes/immunology , Gliosis/immunology , Microglia/immunology , Neuralgia/immunology , Neuritis/immunology , Nociceptors/immunology , Animals , Astrocytes/metabolism , Astrocytes/pathology , Blood-Brain Barrier/immunology , Chronic Pain/chemically induced , Chronic Pain/immunology , Chronic Pain/pathology , Disease Models, Animal , Excitatory Amino Acid Transporter 2/metabolism , Female , Gliosis/chemically induced , Gliosis/pathology , Hyperesthesia/chemically induced , Hyperesthesia/immunology , Hyperesthesia/pathology , Leukocytes/immunology , Leukocytes/pathology , Mice , Mice, Inbred BALB C , Microglia/metabolism , Microglia/pathology , Neuralgia/chemically induced , Neuralgia/pathology , Neuritis/chemically induced , Neuritis/pathology , Proto-Oncogene Proteins c-fos/metabolism , Spinal Cord/immunology , Spinal Cord/metabolism , Spinal Cord/pathology , Zymosan/pharmacology , p38 Mitogen-Activated Protein Kinases/metabolism
17.
Appl Physiol Nutr Metab ; 37(5): 880-7, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22716290

ABSTRACT

While some studies on dietary supplementation with docosahexaenoic acid (DHA, 22:6n-3) have reported a beneficial effect on memory as a function of age, others have failed to find any effect. To clarify this issue, we sought to determine whether supplementing mice with a DHA-enriched diet could alter the ability of synapses to undergo activity-dependent changes in the hippocampus, a brain structure involved in forming new spatial memories. We found that DHA was increased by 29% ± 5% (mean ± SE) in the hippocampus for the supplemented (DHA+) versus nonsupplemented (control) group (n = 5 mice per group; p < 0.05). Such DHA elevation was associated with enhanced synaptic transmission (p < 0.05) as assessed by application of a high-frequency electrical stimulation protocol (100 Hz stimulation, which induced transient (<2 h) increases in synaptic strength) to slices from DHA+ (n = 4 mice) hippocampi when compared with controls (n = 4 mice). Increased synaptic responses were evident 60 min poststimulation. These results suggest that dietary DHA supplementation facilitates synaptic plasticity following brief high-frequency stimulation. This increase in synaptic transmission might provide a physiological correlation for the improved spatial learning and memory observed following DHA supplementation.


Subject(s)
Dietary Supplements , Docosahexaenoic Acids/metabolism , Hippocampus/physiology , Neuronal Plasticity , Neurons/physiology , Nootropic Agents/metabolism , Synaptic Transmission , Animals , CA1 Region, Hippocampal/chemistry , CA1 Region, Hippocampal/physiology , Electric Stimulation/methods , Hippocampus/chemistry , Mice , Mice, Inbred C57BL , Neurons/chemistry , Perfusion , Synaptic Potentials , Time Factors
18.
Brain Behav Immun ; 25(8): 1677-88, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21723939

ABSTRACT

Multiple sclerosis (MS) and the animal model, experimental autoimmune encephalomyelitis (EAE), are both accompanied by motor and non-motor symptoms. Pathological changes in the activities of key neurotransmitters likely underlie many of these symptoms. We have previously described disturbances in the levels of 5-hydroxytryptamine (5-HT/serotonin), noradrenaline (NE) and γ-aminobutyric acid (GABA) in a mouse model of EAE. The potential therapeutic effect of a drug that targets these three neurotransmitters, the antidepressant and anti-panic drug phenelzine (PLZ), was assessed in mice with MOG(35-55) induced EAE. The neurotransmitter content of EAE and control tissue after PLZ administration was first evaluated by HPLC. The ability of PLZ treatment to modulate EAE disease course and clinical signs was then assessed. Daily PLZ treatment, starting seven days after disease induction, delayed EAE onset, reduced disease severity in the chronic phase and was associated with substantial improvements in exploratory behavior and a novel measure of sickness and/or depression. Upon completion of the experiment, PLZ's effects on histopathological markers of the disease were examined. No differences were observed in T cell infiltration, microglia/macrophage reactivity, demyelination or axonal injury in PLZ-treated spinal cords. However, EAE mice treated with PLZ showed a normalization of 5-HT levels in the ventral horn of the spinal cord that might account for the improvements in behavioral outcomes. These results demonstrate the therapeutic potential of MAO inhibitors such as PLZ in MS. Additionally, the behavioral changes observed in EAE mice indicate that alterations in non-motor or 'affective' measures may be valuable to consider in addition to traditional measures of gross locomotor function.


Subject(s)
Encephalomyelitis, Autoimmune, Experimental/drug therapy , Monoamine Oxidase Inhibitors/therapeutic use , Phenelzine/therapeutic use , Affect/drug effects , Animals , Anterior Horn Cells/drug effects , Brain Chemistry/physiology , Chromatography, High Pressure Liquid , Disease Progression , Encephalomyelitis, Autoimmune, Experimental/metabolism , Encephalomyelitis, Autoimmune, Experimental/pathology , Female , Gliosis/pathology , Image Processing, Computer-Assisted , Immunohistochemistry , Inflammation/pathology , Mice , Mice, Inbred C57BL , Motor Activity/physiology , Norepinephrine/metabolism , Postural Balance/physiology , Recovery of Function , Serotonin/metabolism , Spinal Cord/pathology , Treatment Outcome , gamma-Aminobutyric Acid/metabolism
19.
Neurochem Int ; 59(1): 28-38, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21672584

ABSTRACT

We have characterized the changes in tissue concentrations of amino acids and biogenic amines in the central nervous system (CNS) of mice with MOG(35-55)-induced experimental autoimmune encephalomyelitis (EAE), an animal model commonly used to study multiple sclerosis (MS). High performance liquid chromatography was used to analyse tissue samples from five regions of the CNS at the onset, peak and chronic phase of MOG(35-55) EAE. Our analysis includes the evaluation of several newly examined amino acids including d-serine, and the inter-relations between the intraspinal concentration changes of different amino acids and biogenic amines during EAE. Our results confirm many of the findings from similar studies using different variants of the EAE model as well as those examining changes in amino acid and biogenic amine levels in the cerebrospinal fluid (CSF) of MS patients. However, several notable differences were observed between mice with MOG(35-55)-induced EAE with findings from human studies and other EAE models. In addition, our analysis has identified strong correlations between different amino acids and biogenic amines that appear to change in two distinct groups during EAE. Group I analyte concentrations are increased at EAE onset and peak but then decrease in the chronic phase with a large degree of variability. Group II is composed of amino acids and biogenic amines that change in a progressive manner during EAE. The altered levels of these amino acids and biogenic amines in the disease may represent a critical pathway leading to neurodegenerative processes that are now recognized to occur in EAE and MS.


Subject(s)
Amino Acids/metabolism , Biogenic Amines/metabolism , Central Nervous System/metabolism , Encephalomyelitis, Autoimmune, Experimental/metabolism , Amino Acids/cerebrospinal fluid , Animals , Biogenic Amines/cerebrospinal fluid , Encephalomyelitis, Autoimmune, Experimental/cerebrospinal fluid , Female , Mice , Mice, Inbred C57BL
20.
Learn Mem ; 17(12): 627-38, 2010 Dec.
Article in English | MEDLINE | ID: mdl-21097606

ABSTRACT

The capacity for long-term changes in synaptic efficacy can be altered by prior synaptic activity, a process known as "metaplasticity." Activation of receptors for modulatory neurotransmitters can trigger downstream signaling cascades that persist beyond initial receptor activation and may thus have metaplastic effects. Because activation of ß-adrenergic receptors (ß-ARs) strongly enhances the induction of long-term potentiation (LTP) in the hippocampal CA1 region, we examined whether activation of these receptors also had metaplastic effects on LTP induction. Our results show that activation of ß-ARs induces a protein synthesis-dependent form of metaplasticity that primes the future induction of late-phase LTP by a subthreshold stimulus. ß-AR activation also induced a long-lasting increase in phosphorylation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) GluA1 subunits at a protein kinase A (PKA) site (S845) and transiently activated extracellular signal-regulated kinase (ERK). Consistent with this, inhibitors of PKA and ERK blocked the metaplastic effects of ß-AR activation. ß-AR activation also induced a prolonged, translation-dependent increase in cell surface levels of GluA1 subunit-containing AMPA receptors. Our results indicate that ß-ARs can modulate hippocampal synaptic plasticity by priming synapses for the future induction of late-phase LTP through up-regulation of translational processes, one consequence of which is the trafficking of AMPARs to the cell surface.


Subject(s)
Excitatory Postsynaptic Potentials/physiology , Long-Term Potentiation/physiology , Receptors, AMPA/metabolism , Receptors, Adrenergic, beta/metabolism , Adrenergic beta-Agonists/pharmacology , Adrenergic beta-Antagonists/pharmacology , Animals , Biophysics , Carbazoles/pharmacology , Electric Stimulation/methods , Enzyme Inhibitors/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Excitatory Postsynaptic Potentials/drug effects , Hippocampus/drug effects , Hippocampus/physiology , In Vitro Techniques , Isoproterenol/pharmacology , Long-Term Potentiation/drug effects , Male , Mice , Mice, Inbred C57BL , Patch-Clamp Techniques/methods , Phosphorylation/drug effects , Phosphorylation/physiology , Propranolol/pharmacology , Pyrroles/pharmacology , Serine/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...